Table 1.

Correlation between FGFR2 gene amplification and sensitivity to AZD4547 in a range of standard and PDGCX xenograft models

AZD4547
12.5 mg/kg
ModelFGFR2 status (by FISH)TGI, %Tumor regression, %
SNU-16Amplified>10064b
AZ521Disomy63
MGC803Disomy37
SGC083aAmplified>10090c
G001aPolysomy34
G009aTrisomy23
  • aPDGCX model.

  • bTumor regression was assessed at the end of the study.

  • cAZD4547 was administered for 7 days and tumor regression was assessed on day 25 after first dose.